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A STAT3-decoy oligonucleotide induces cell death
in a human colorectal carcinoma cell line by
blocking nuclear transfer of STAT3 and STAT3-
bound NF-B
Inès Souissi1,2, Imen Najjar6,7, Laurent Ah-Koon1,2, Pierre Olivier Schischmanoff1,2,3†, Denis Lesage1,2†,
Stéphanie Le Coquil1,2, Claudine Roger4, Isabelle Dusanter-Fourt6,7, Nadine Varin-Blank1,2, An Cao8, Valeri Metelev5,
Fanny Baran-Marszak1,2,4 and Remi Fagard1,2,3*
Abstract
Background: The transcription factor STAT3 (signal transducer and activator of transcription 3) is frequently
activated in tumor cells. Activated STAT3 forms homodimers, or heterodimers with other TFs such as NF-B, which
becomes activated. Cytoplasmic STAT3 dimers are activated by tyrosine phosphorylation; they interact with
importins via a nuclear localization signal (NLS) one of which is located within the DNA-binding domain formed by
the dimer. In the nucleus, STAT3 regulates target gene expression by binding a consensus sequence within the
promoter. STAT3-specific decoy oligonucleotides (STAT3-decoy ODN) that contain this consensus sequence inhibit
the transcriptional activity of STAT3, leading to cell death; however, their mechanism of action is unclear.
Results: The mechanism of action of a STAT3-decoy ODN was analyzed in the colon carcinoma cell line SW 480.
These cells’ dependence on activated STAT3 was verified by showing that cell death is induced by STAT3-specific
siRNAs or Stattic. STAT3-decoy ODN was shown to bind activated STAT3 within the cytoplasm, and to prevent its
translocation to the nucleus, as well as that of STAT3-associated NF-B, but it did not prevent the nuclear transfer
of STAT3 with mutations in its DNA-binding domain. The complex formed by STAT3 and the STAT3-decoy ODN
did not associate with importin, while STAT3 alone was found to co-immunoprecipitate with importin. Leptomycin
B and vanadate both trap STAT3 in the nucleus. They were found here to oppose the cytoplasmic trapping of
STAT3 by the STAT3-decoy ODN. Control decoys consisting of either a mutated STAT3-decoy ODN or a NF-B-
specific decoy ODN had no effect on STAT3 nuclear translocation. Finally, blockage of STAT3 nuclear transfer
correlated with the induction of SW 480 cell death.
Conclusions: The inhibition of STAT3 by a STAT3-decoy ODN, leading to cell death, involves the entrapment of
activated STAT3 dimers in the cytoplasm. A mechanism is suggested whereby this entrapment is due to STAT3-
decoy ODN’s inhibition of active STAT3/importin interaction. These observations point to the high potential of
STAT3-decoy ODN as a reagent and to STAT3 nucleo-cytoplasmic shuttling in tumor cells as a potential target for
effective anti-cancer compounds.
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Background
STAT3 belongs to the signal transducers and activators
of transcription (STATs) family of transcription factors
(TFs) [1]. STAT3 is activated in response to several
cytokines and growth factors, including IL-6, epidermal
growth factor (EGF), and interferon (IFN) a; STAT3 is
also weakly activated in response to other cytokines,
including IFNg. Activation of STAT3 results from the
phosphorylation of tyrosine 705, mediated by Janus
Kinases (JAK), which are associated to cytokine recep-
tors, and also by the Src and Abelson (Abl) families of
protein tyrosine kinases [2]. STAT3 is also phosphory-
lated on serine 727, sometimes resulting in its activa-
tion. Following phosphorylation, STAT3 dimerizes and
enters the nucleus by interacting with nuclear import
proteins [3] of the karyopherin/importin family [4]. The
importins interact with nuclear localization signals
(NLS), one of which is located within the DNA binding
domain (DBD) of STAT3 and is thought to be the most
efficient [3,5]. Once in the nucleus, STAT3 activates the
transcription of its target genes, including cyclin D1,
survivin, VEGF, c-myc, Bcl-xL, and Bcl2 (see [6] for
review). Once released from its DNA targets, STAT3 is
dephosphorylated in the nucleus [7] and exported to the
cytoplasm by a CRM1-dependent process [8]. STAT3
has been described as a key regulator of cell survival
and proliferation [9]; its constitutive activation has been
observed in many human tumors, including colon,
breast, lung, pancreas and prostate cancers, melanoma,
head and neck squamous carcinoma, multiple myeloma,
mantle cell lymphoma, and glioma [10,11]. In addition,
substituting amino acids located at the STAT3 dimer
interface for cysteines yielded a stabilized STAT3 dimer
that was able to induce a pseudotransformed phenotype
[12]. Thus, its constitutive activation in tumor cells
points to STAT3 as a valuable target for attacking
tumor cells. Furthermore, despite its essential role in
development [13], STAT3 is not essential for the func-
tioning of mature cells [14]. Some STAT3 inhibitors are
not specific, such as curcumin [15]. In contrast, Stattic,
which prevents STAT3 dimerization by specifically
interacting with its SH2 domain [16], is highly specific,
and efficiently induces tumor cell death [16,17]. Despite
its frequent involvement in cancer, which makes it a
highly valuable target for inducing tumor cell death,
STAT3 still lacks more specific inhibitors. Besides the
SH2 domain, another potential target for highly selective
STAT3 inhibitors is its DBD, since it selectively recog-
nizes and binds DNA motifs in target genes. Decoy oli-
gonucleotides (decoy ODNs) containing the TFs’ DNA
binding consensus sequences selectively inhibit them by
binding to the DBD [18]. They can induce, in vitro, the
death of tumor cells whose growth depends on these
TFs [19]. This has notably been shown for several TFs,
including NF-B [20,21] and STAT3 [17,22-24].
STAT3-decoy ODN efficiently induced cell death in
mouse xenografts of a head and neck squamous cell car-
cinoma [25]. One limitation of STAT3-decoy ODN is
that despite the different functions of STAT1 and
STAT3 in the cell, they recognize very similar DNA tar-
gets [26], with the result that STAT3-decoy ODN can
inhibit either one or the other. For example, in the
colon carcinoma cell line SW 480, the constitutive acti-
vation of STAT3 contributes to cell survival; its inhibi-
tion by STAT3-decoy ODN induces cell death.
However, the ODN also blocks IFNg-mediated cell
death through STAT1 activation in the same cell line
[17]. The actual mechanism through which decoy ODNs
inhibit TFs is still unclear. Of the many studies demon-
strating decoy ODN-mediated inhibition of TFs such as
E2F, NF-B [27], CRE and AP1 [28], none have specifi-
cally investigated the subcellular localization required
for decoy ODNs to exercise their inhibitory action. A
study on AP1 suggested that nuclear entry is required
for decoy ODNs to inhibit targeted TFs [29]. Another
study showed that a decoy ODN engineered to contain
a nuclear localization signal (NLS) could enter the
nucleus and efficiently inhibit p53 [30]. It is not clear
yet whether these requirements depend on cellular sys-
tems or on the TFs that are targeted, since other studies
have found that decoy ODNs did not have to enter the
nucleus to exert their inhibitory effect [17,21]. In order
to assess their possible use in human cancer, it will be
important to understand the mechanism through which
the decoy ODNs interfere with TFs and to determine
whether nucleo-cytoplasmic shuttling is impaired. In the
case of STAT3, constitutive shuttling from cytoplasm to
nucleus has been demonstrated [8,31]. Furthermore,
STAT3’s localization seems to be predominantly nuclear
[32], indicating that the shuttling mechanism could be a
promising target for achieving effective STAT3 inhibi-
tion, as previously suggested [33]. Decoy ODNs’
mechanism of action on STAT3 was therefore studied
to determine whether nucleo-cytoplasmic shuttling was
impaired, leading to STAT3 inhibition. Finally, since
STAT3 has been reported to interact and synergize with
NF-B [34] in tumor cells [35], this study also addresses
the functional interplay of NF-B and decoy ODN.
Methods
Cell culture and reagents
SW 480 (colon adenocarcinoma) and MCF-7 (breast
cancer) cell lines were grown in DMEM (GibcoBRL, Life
technologies, Cergy-Pontoise, France), supplemented
with 10% FCS (Lonza, Levallois-Perret, France) 100 U/
mL penicillin, 10 μg/mL streptomycin (GibcoBRL), 1
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mM sodium pyruvate (GibcoBRL), MEM vitamins 100 ×
(GibcoBRL) and 5 μg/mL plasmocin (Cayla InvivoGen,
Toulouse, France). The KG-1 cells were grown in 10%
FCS supplemented IMDM medium (GibcoBRL). For the
STAT3 overexpression experiments the plasmid
PLZst3a was used. The STAT3 DNA binding domain
(DBD)-mutant containing two mutations in the DBD
that completely prevented DNA binding but allowed
dimerization and nuclear entry, was a kind gift from Dr.
C. Horvath (Northwestern University, Chicago, USA)
[36]. For some experiments, cells were treated with
TNFa (20 ng/ml) (Sigma-Aldrich, Montigny le Breton-
neux, France). To enhance STAT3 activation, cells were
treated for 1 hr with IL-6 (50 ng/ml) (Sigma). Sodium
orthovanadate (100 μM) (stock solution: 100 mM) was
from Fischer (Illkirch, France), leptomycin B (LMB) (10
ng/ml) was from Sigma-Aldrich.
RNA silencing
For cell infection with lentiviral shRNA, a set of two
STAT1-targeting shRNAs that has previously been
found to reduce the expression of STAT1 [37] was used
and transduced as previously described [37]. Efficiency
of infection was verified by measuring GFP by flow cyto-
metry, and the efficacy of the inhibition of the shRNA’s
inhibition of STAT1 expression was verified by western
blotting using a STAT1-specific antibody (Cell Signaling,
Ozyme, St Quentin Fallavier, France).
For siRNA STAT3 silencing, the following double
stranded siRNA oligonucleotide, previously shown to
suppress STAT3 expression in a colorectal cell line [38],
was purchased from Sigma-Aldrich: 5’-AACAUCUGC-
CUAGAUCGGCUAdTdT-3’; 3’-dTdTGUAGACGGAU-
CUAGCCGAU-5’, along with a universal control set of
siRNA (Sigma Aldrich). Cells (105 cells/well; density:
60%) were transfected using polyethylene imine (PEI)
with 10 nM siRNA in culture medium without antibio-
tics. After 48 h or 72 h, cells were harvested and ana-
lyzed for annexin V binding by flow cytometry. In
control cells, the irrelevant control siRNA was used. All
experiments were performed in triplicate.
Preparation of subcellular fractions
Cells (20 × 106) were resuspended in cell lysis buffer
containing 20 mM Hepes pH 7.4, 1 mM MgCl2, 10 mM
KCl, 0.3% NP40, 0.5 mM DTT, 0.1 mM EDTA and pro-
tease inhibitors (CompeteTM, Boerhinger, France), and
placed at 4°C for 5 min. The lysates were centrifuged at
14000 g for 5 min at 4°C, and the supernatant contain-
ing the cytoplasmic fraction was stored in aliquots at
-80°C. The pellets were resuspended in cell lysis buffer
adjusted to 20% glycerol and 0.35 M NaCl and placed at
4°C for 30 min. After centrifugation at 14000 g for 5
min at 4°C, the supernatant, containing the nuclear
proteins, was stored at -80°C. Protein amounts were
determined before use with the micro-BCA protein
determination kit (Pierce, Perbio, Brebières, France).
Decoy oligonucleotides
The STAT3-decoy ODNs used were: RHN(CH2)6-
CATTTCCCGTAAATCGAAGATTTACGGGAAATG
-(CH2)3NHR (hp STAT3-decoy ODN), derived from the
serum-inducible element of the human c-fos promoter
[39], and RHN(CH2)6- CATTTGCCACAATCGAA-
GATTGTGGCAAATG -(CH2)3NHR (hairpin STAT3-
decoy mutated ODN) (Sigma-Proligo) where R was
either H, FITC or biotin. The decoy NF-B-ODN con-
sisted of: RNH(CH2)6-CTGGAAAGTCCCTCGAA-
GAGGGACTTTCCAG-(CH2)3NHR (hairpin decoy NF-
B-ODN) and RHN(CH2)6-TGCAGTCACTACGC-
GAAGCGTAGTGACTGCA-(CH2)3NHR (hairpin
scrambled decoy NF-B-ODN) where R is either H or
biotin. The synthesis of decoy oligonucleotides with R =
H has been published elsewhere [17]. For biotin addi-
tion, 7-10 nanomoles of the oligodeoxynucleotide bear-
ing 3’- and 5’-aminoalkyl linkers were dissolved in 20 μL
of 0.1 M NaHCO3. EZ-Link NHS-biotin (Pierce, Rock-
ford, USA) (10 μL of a 65 mM solution in dimethyl sulf-
oxide) was added, and the mixture was incubated at
room temperature for 6-16 h in the dark. Then 25 μL of
water were added, and the modified oligodeoxynucleo-
tide was separated from the excess of hydrolyzed
reagent by two consecutive separations on Micro Bio-
Spin 6 columns following the manufacturer’s recom-
mendations. After the second spin, the biotinylated oli-
godeoxynucleotide was precipitated with ethanol-sodium
acetate. In control experiments the previously published
decoy NF-B-ODN [21] was used. In some cases FITC-
labeled or biotinylated decoy ODNs were obtained from
Sigma-Aldrich. Note that the oligonucleotides used for
cell death induction, pull-down assays and whole-cell
pull-down assays were similar and could be used inter-
changeably, except that for pull-down biotinylated oligo-
nucleotides had to be used.
Preparation of liposomes
Liposomes were formulated using a cationic lipid (3b-
[N-(N’,N’,N’-triethylaminopropane)-carbamoyl] choles-
terol) iodide (TEAPC-Chol) and neutral colipid dioleoyl
phosphatidylethanolamine (DOPE), as previously
described [40]. The concentration of cationic lipid was
monitored by UV spectroscopy at 226 nm and the value
was used to calculate the charge ratio assuming one
positive charge for each cationic lipid molecule.
Gel electrophoresis, western blotting
Cells were washed in PBS, lysed in sample buffer (50
mM Tris-HCl pH 6.8 (Bio-Rad, Marnes-la-Coquette,
Souissi et al. BMC Cell Biology 2011, 12:14
http://www.biomedcentral.com/1471-2121/12/14
Page 3 of 18
France), 2% sodium dodecyl sulfate (SDS) (Sigma-
Aldrich), 20% glycerol (Prolabo, Fontenay-sous-Bois,
France), 1 mM sodium vanadate (Na3VO4, Labosi, Elan-
court, France), 1 mM dithiothreitritol (DTT) (Merck,
Fontenay Sous Bois, France) and 0.01% bromophenol
blue (Sigma-Aldrich), sonicated and stored at -70°C.
Proteins (50 μg) were separated on SDS-PAGE (10%)
and transferred onto nitrocellulose membranes; mem-
branes blocked with 5% dry skimmed milk in TBS were
incubated with antibody overnight at 4°C. Anti-phos-
photyrosine 705-STAT3 (1/1,000), anti-STAT3 (1/
1,000), anti-NF-B p50 (1/1,000), anti-NF-B p65 (1/
1,000), anti-STAT1 (1/1,000), and anti-OCT1 (1/1,000)
were from Cell Signaling, anti-karyopherin/importin a
(1:400) was from Santa Cruz (Tebu-bio, Le Perray en
Yvelines, France). Blots were washed in TBS-T, incu-
bated with peroxidase-coupled goat anti-mouse (Santa
Cruz, Tebu-bio) or goat anti-rabbit (Upstate, Ozyme)
secondary antibody (1/20,000) washed in TBS-T and
revealed by chemiluminescence (LumiGLO reagent and
peroxide; Cell Signaling) and autoradiography (X-Omat
R film; Kodak). When necessary, membranes were
stripped with Blot Restore Kit (Chemicon International)
and reprobed with anti-actin antibody (Cell Signaling).
Prestained molecular weight standards (Fermentas,
Saint-Rémy-lès-Chevreuse, France) were used. For the
quantification analysis, the bands from at least three
separate experiments were scanned using a Chemidoc
apparatus (Biorad) and quantification performed using
the Quantity One software (Biorad). P-values were cal-
culated using a t test.
Real-time qPCR
The TaqMan® Gene Expression Cells-to-CT™ kit
(Applied Biosystems, Courtaboeuf, France) was used to
extract total RNA and to perform reverse transcription
and gene amplification. An Applied Biosystems Custom
TaqMan Gene Expression Assay was used; the
sequences were chosen to cover exons 5 and 6 to avoid
detecting genomic DNA: sense primer: 5’-ccatcttcatca-
cactcttcctgtt, antisense primer: 5’-accaccgaggagaagatcca,
5’-FAM probe: 5-ctacagtgccaccgtcacc. For the TaqMan
Gene Expression Assay (Applied Biosystems) ref.
Hs00941525_g1 was used. For cyclophilin A (PPIA),
used as a reference, the TaqMan Gene Expression
Assay, ref. Hs99999904_m1 was used. All steps were
performed following the recommendations of the manu-
facturer. Relative expression levels of each gene were
calculated as previously described.
Transfections
Cells were grown in 4-well plates to a density of 0.5 106
cells/mL. When the cells reached 50-60% confluence,
they were transfected with STAT3-decoy ODN or the
hairpin control decoy ODN (2 μg corresponding to 400
nM) in 150 μL of DMEM medium (without SVF) com-
bined with the liposomes (2 μg of cationic lipid). After 6
h at 37°C in a humidified 5% CO2 incubator, the cells
were placed in fresh serum-containing medium. Expres-
sion was analyzed after 48 h. In other cases, transfection
was performed using polyethyleneimine (PEI, Sigma-
Aldrich), with an ODN-to-polyethyleneimine ratio of
1:1.
Flow cytometry, cell viability, immunocytochemistry
To measure cell death, cells were resuspended in
annexin V-binding buffer, incubated with 5 μL of propi-
dium iodide (BD Pharmingen, Morangis, France) and
subjected to flow cytometry analysis, using a BD FACS
Canto II Flow Cytometer. Cell viability was also assessed
using the trypan-blue exclusion method with a V-cell
counter (Beckmann, Villepinte, France).
For immunocytochemistry, cells were grown in 8-well
plates (lab-tek, Nunc, Rochester, USA) to a density of
0.5 106 cells/mL. At 50-60% confluence, cells were
transfected with the FITC-labeled STAT3-decoy ODN
or the FITC-labeled mutated STAT3-decoy ODN. After
48 h the cells were washed in NaCl-phosphate buffer,
fixed in 3.7% formaldehyde for 15 mn, permeabilized in
0.1% Triton X-100 for 15 mn and blocked in 5% FCS,
0.1% Tween in NaCl-phosphate buffer for 1 h. Cells
were stained with anti-STAT3 antibody (Cell Signaling)
(dilution: 1:100) or anti- phosphotyrosine 705-STAT3
antibody (Cell Signaling) (1:100) for 2 h and Alexa Fluor
546-labeled secondary antibody (Invitrogen) (1:200) for
90 mn. After counterstaining with 4’, 6’- diamidino-2-
phenylindole (DAPI) coverslips were mounted onto
glass slides with Vectashield (Vectorlabs, Clinisciences,
Montrouge, France). Fluorescence images were acquired
using a Zeiss Axioplan2 Deconvolution microscope
(Carl Zeiss, Le Pecq, France) and analyzed with Meta-
fer4 (Metasystems, Altlussheim, Germany).
Oligodeoxynucleotide pull-down
Nuclear protein extracts were obtained as follows: 20
million cells were resuspended in lysis buffer (20 mM
Hepes, pH 7.4, 1 mM MgCl2, 10 mM KCl, 0.3% NP40,
0.5 mM dithiothreitol, 0.1 mM EDTA, protease inhibi-
tors: Compete™, Boerhinger) at 4°C for 20 min. The
lysates were centrifuged at 14 000 × g for 5 min at 4°C,
and the supernatants containing the cytoplasmic pro-
teins were discarded. The pellets were resuspended in
the cell lysis buffer adjusted with 20% glycerol and 0.35
M NaCl for 30 min at 4°C. After centrifugation at 14
000 × g for 5 min at 4°C, the supernatants were stored
at -80°C. For pull-down assays, 100-200 μg of nuclear
protein extracts were incubated for 30 min at 4°C in
binding buffer (1% NP40, 50 mM Hepes, pH 7.6, 140
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mM NaCl) containing salmon sperm DNA (1 μg/assay)
and 1 μg of the biotinylated hairpin decoy ODN or the
mutated decoy ODN. The complexes were captured by
incubation with 50 μl of avidin-Sepharose beads (neutra-
vidin, Pierce) for 2 h at 4°C. For in-cell decoy ODN
pull-down assays, the cells were first transfected with
STAT3-decoy ODN or its mutated equivalent, as
described under oligonucleotide transfection (see above),
and then processed as above by cell lysis and recovery
on avidin-Sepharose beads. After extensive washing with
binding buffer, complexes were separated on SDS-polya-
crylamide (8%) gel, and subjected to immunoblotting
using an anti-STAT3 antibody (Cell Signaling). Results
were analyzed by chemiluminescence (LumiGLO, Cell
Signaling) and autoradiography (X-Omat R, Kodak).
Antibody co-immunoprecipitation
For antibody pull-down assays, 20 million cells were
lyzed and resuspended in lysis buffer (20 mM Hepes,
pH 7.4, 1 mM MgCl2, 10 mM KCl, 1% NP40, 0.5 mM
dithiothreitol, 0.1 mM EDTA, 1 mM orthovanadate,
protease inhibitors; Compete™, Boerhinger) at 4°C for 5
min. The lysates were centrifuged at 14 000 × g for 5
min at 4°C, and the supernatants containing the cyto-
plasmic proteins were either used immediately or stored
at -80°C. For the immunoprecipitations, 200 to 400 μg
protein was supplemented with albumin-saturated pro-
tein G-agarose (Boehringer); after centrifugation (8000 ×
g, 5 min), the pellet was discarded and the supernatant
conserved. Antibody was added (STAT3: 1:100; karyo-
pherin, Santa-Cruz: 1:40) and incubation continued
overnight at 4°C. Samples were then supplemented with
albumin-saturated protein G-agarose and incubated for
1 h 30 m. The agarose beads were washed three times
with TBS and once with TBS-T, and resuspended in
SDS-sample buffer. Gel separation and western blotting
were performed as described above.
Results
Survival of SW 480 colon carcinoma cells requires
activated STAT3
STAT3 is activated in colon carcinoma and in the colon
carcinoma cell line SW 480 [17,41]. In SW 480 cells
transfected with specific STAT3 siRNA, the expression
of STAT3 was strongly reduced (Figure 1A) and the
number of annexin V-positive cells was significantly
increased in comparison to cells treated with control
siRNA (Figure 1B). STAT3 tyrosine 705 phosphorylation
was detected (Figure 1C) as previously reported [17,41].
Pull-downs with biotinylated ODN were performed, fol-
lowed by western blotting with anti-STAT3 antibody.
This method is analogous to gel retardation assays, and
revealed that STAT3 is activated. ODN-bound activated
STAT3 was detected in nuclear extracts from untreated
(Figure 1D, lane 2) and IL-6-treated cells (lane 4); cyto-
plasmic STAT3 only weakly bound the biotinylated
ODN (Figure 1D, lanes 1 and 3). Treatment of cells
with the STAT3 inhibitor Stattic (20 μM), known to
inhibit STAT3 phosphorylation and dimerization [16],
inhibited the nuclear translocation of STAT3 in SW 480
cells (Figure 1E, lane 4, see also figure threeD), as pre-
viously shown in other cell lines [16]; this correlated
with induction of cell death (Figure 1F).
Cytoplasmic sequestration of STAT3 and phospho-STAT3
by STAT3-decoy ODN
The subcellular distribution of STAT3-decoy ODN in
SW 480 cells was shown by fluorescence microscopy to
be essentially cytoplasmic (see [additional file 1], and
figures 2B and 2C). Immunofluorescence microscopy
analyzis of the subcellular localization of phospho-
STAT3 in untreated SW480 cells showed that it was
essentially nuclear (Figure 2A), but following STAT3-
decoy ODN treatment it became mostly cytoplasmic
(Figure 2B), this was not observed when using mutated
STAT3-decoy ODN (Figure 2C). Pull-down experiments
within cells transfected with biotinylated STAT3-decoy
ODN followed by western blotting showed that phos-
pho-STAT3 interacted with STAT3-decoy ODN (Figure
2D). In these experiments, the binding of phospho-
STAT3 to the STAT3-decoy ODN was blocked by the
treatment of cells with Stattic (10 and 20 μM), known
to prevent STAT3 dimer formation [16], indicating that
the STAT3-decoy ODN binds activated STAT3 dimers
(Figure 2D). Total STAT3 was almost exclusively
nuclear in untreated cells (Figure 3A), but after treat-
ment with STAT3-decoy ODN it became cytoplasmic
(Figure 3B). This was not observed when using mutated
STAT3-decoy ODN (Figure 3C) but was observed when
treating cells with Stattic (Figure 3D). Subcellular locali-
zation of STAT3 studied by cell fractionnation and wes-
tern blotting showed that STAT3-decoy ODN efficiently
prevented STAT3 nuclear translocation (Figure 3E, lane
4), whereas neither a mutated STAT3-decoy ODN (lane
6), nor a NF-B-decoy ODN did so (Figure 3F, lane 4).
A diagram of the data collected from several experi-
ments illustrates the effect of STAT3-decoy ODN on
the nucleo-cytoplasmic distribution of STAT3: in
STAT3-decoy ODN-transfected cells nuclear STAT3
consisted of 20% of the total STAT3 (Figure 3G); con-
versely, in control-, mutated decoy ODN-, and NF-B-
decoy ODN-transfected cells, it consisted of 50% of the
total STAT3, suggesting that STAT3-decoy ODN func-
tions by trapping STAT3 within the cytoplasm. Finally,
the binding of STAT3 to biotinylated STAT3-decoy
ODN within cells was blocked by addition of excess
non-biotinylated STAT3-decoy ODN (Figure 3H, and
[additional file 2]).
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Figure 1 STAT3 activation is required for SW 480 colon carcinoma cell survival. A: Western blotting of STAT3 in cells not transfected with
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iodide (PI)-positive cells in the absence of transfection (NT), or after transfection with STAT3 siRNA (siRNA) or control siRNA (ctRNA). A typical
experiment is shown. C: Western blotting of phospho-STAT3 and STAT3 in cytoplasmic (C) and nuclear (N) fractions of non-treated SW 480 cells.
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Cytoplasmic sequestration of STAT3 and phospho-STAT3
by STAT3-decoy ODN correlates with STAT3 inhibition
and cell death
In STAT3-decoy ODN-transfected SW 480 cells, cell
death increased (Figure 4A), as previously shown in
these [17] and other cells [22-24]. STAT3-decoy ODN
also induced cell death of MCF-7 cells, in which a low
but detectable STAT3 activation has been previously
observed [42]. However, the STAT3-decoy ODN had no
effect on the acute myeloid leukemia cell line KG1, in
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localization of phospho-STAT3 (red) in non-treated SW 480 cells. Cells were fixed and labelled with anti-phosphotyrosine 705-STAT3 antibody
and counterstained with 4’,6’-diamidino-2-phenylindole (Dapi); B: cytoplasmic localization of phospho-STAT3 (red) in STAT3-decoy ODN-
transfected (2 μg/ml) SW480 cells; FITC-labeled STAT3-decoy ODN was detected in the cytoplasm (green), and cells counterstained with Dapi; C:
nuclear localization of STAT3 (red) in mutated STAT3-ODN- transfected (2 μg/ml) SW480 cells; FITC-labeled mutated STAT3-ODN was detected in
the cytoplasm (green), cells were counterstained with Dapi. Scale bar: 10 nm. In-cell STAT3-decoy ODN pull-down assays: D: Cells were
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Figure 3 Inhibition of STAT3 nuclear localization by STAT3-decoy ODN. A: Nuclear localization of STAT3 (red) in non-treated SW 480 cells.
Cells were fixed and labelled with anti-STAT3 antibody; B: cytoplasmic localization of STAT3 (red) in STAT3-decoy ODN- transfected (2 μg/ml)
SW480 cells; FITC-labeled STAT3-decoy ODN was detected in the cytoplasm (green); C: nuclear localization of STAT3 (red) in mutated STAT3-
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STAT3 in Stattic-treated cells (20 μM). Nuclei stained with DAPI. Scale: 10 nm. E: Cells transfected with STAT3-decoy ODN and STAT3 determined
in cytoplasm and nucleus: no treatment (1 and 2), STAT3-decoy ODN 2 μg/ml (3 and 4), mutated STAT3-decoy ODN (mtODN) 2 μg/ml (5 and 6).
OCT-1 antibody reprobing to check for cytoplasmic contamination. A typical result is shown. F: Cells were untreated (1 and 2), transfected with
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p values, n>3. H: Cells transfected with biotinylated STAT3-decoy ODN (1, 2 and 3) or its mutated equivalent (4) and complexes recovered and
analyzed as in D; cells co-transfected with competitor: non-biotinylated STAT3-decoy ODN (2) or its mutated equivalent (3).
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which STAT5, rather than STAT3, is activated [43]
(Figure 4A). The mutated STAT3-decoy ODN had no
effect in any of the three cell lines (Figure 4A). The
STAT3-target cyclin-D1 was analyzed by qPCR in
STAT3-decoy ODN-transfected SW 480 cells: reduced
cyclin-D1 expression was observed, similar to that
observed with Stattic (Figure 4B). This suggests that it is
the cytoplasmic trapping of STAT3 by the STAT3-
decoy ODN which leads to cell death. Since STAT3-
decoy ODN can also bind STAT1 and prevent STAT1-
dependent IFNg-induced cell death [17], experiments
were performed to determine the overall involvement of
STAT1 in STAT3-decoy ODN-induced cell death. To
this end, STAT1 was silenced using shRNA in the SW
480 cells. As previously described in other cell systems
[37], the expression of STAT1 was suppressed by speci-
fic shRNA, and not by empty vector; NF-B and STAT3
expression was unchanged (Figure 5A). In STAT1-
silenced SW 480 cells, the basal level of dead cells was
unchanged. However, STAT3-decoy ODN-induced cell
death was suppressed (Figure 5B). There was no effect
of the mutated STAT3-decoy ODN, but IFNg-induced
cell death was suppressed (Figure 5B). Thus, STAT1
expression is important for cell death induction by
STAT3 inhibitors, in agreement with observations pub-
lished elsewhere [44], and in line with the notion that
STAT1 is a key component of the cellular mechanism
leading to cell death [45,46].
Blockage of STAT3 nuclear transfer by STAT3-decoy ODN
is overcome by IL-6-mediated activation of STAT3 or
increased expression of recombinant STAT3
To evaluate the relevance of STAT3-decoy ODN/
STAT3 interaction in the reduction of nuclear STAT3,
cells were transfected with STAT3-decoy ODN and
treated with IL-6, and nuclear STAT3 was analyzed.
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Figure 5 Involvement of STAT1 expression level in STAT3-
decoy ODN-induced cell death. Colon carcinoma SW 480 cells
transduced either with control virus (black histograms) or with
STAT1-specific shRNA (white histograms). A: Detection of STAT1 by
western blotting of control cells (1), cells transduced with an empty
virus (Ev) (lane 2), and with a STAT1-specific shRNA lentivirus (3).
Below are shown the detection of STAT3, the NF-B (p50 subunit)
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h). Data are expressed in % of dead cells.
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Treatment with IL-6 significantly increased the tyrosine
phosphorylation of STAT3; inhibition of STAT3 nuclear
transfer by STAT3-decoy ODN was partially overcome
by this treatment (Figure 6A), suggesting a titrating
effect of the increased amount of active STAT3 on
STAT3-decoy ODN action. Similarly, overexpression of
STAT3 by plasmid transfection of SW 480 cells resulted
in a marked increase of STAT3 nuclear localization
(Figure 6B, lane 2) and considerably reduced inhibitory
effects of STAT3-decoy ODN (lane 5) and Stattic (lane
6). However, when more STAT3-decoy ODN (4 μg) was
added to STAT3-overexpressing cells, a reduction of
nuclear STAT3 was observed (Figure 6C, lane 6). Con-
versely, in cells transfected with DBD-mutated STAT3,
there was no change in nucleo-cytoplasmic distribution
after treatment with STAT3-decoy ODN (Figure 6D,
lane 6). This emphasizes the notion that a functional
DBD is necessary for STAT3-decoy ODN to prevent
STAT3 nuclear localization. Cell death was also ana-
lyzed to determine whether modifications of STAT3’s
subcellular localization affected cell fate. Overexpression
of STAT3 in SW 480 cells significantly reduced the rate
of cell death induced by STAT3-decoy ODN or by Stat-
tic (5 μM) (Figure 6E). Combining the cell death data
shown in Figure 6E with the amounts of nuclear STAT3
of Figure 6B showed that nuclear accumulation of
STAT3 is inversely proportional to cell death (Figure
6F). Overall, these experiments suggest that STAT3-
decoy ODN-induced cell death results from the inhibi-
tion of STAT3 through its entrapment within the
cytoplasm.
STAT3-decoy ODN interferes with the cytoplasmic-nuclear
shuttling of STAT3
Nuclear transfer of activated STAT3 through nuclear
pores is dependent on nuclear import involving karyo-
pherin/importins, which interact with STAT3’s NLS; the
NLS located within the DBD being the most efficient in
STAT3 [3,5]. The activated STAT3 dimer enters the
nucleus, binds its DNA targets, and is then released,
after which it is dephosphorylated by a nuclear tyrosine
phosphatase [7]; inhibition of the phosphatase with
vanadate traps STAT3 in the nucleus (shown by
increased nuclear phospho-STAT3 in vanadate-treated
SW480 cells, see supplemental data 3). The transfer of
STAT3 to the cytoplasm depends in part on the export
protein CRM1 [47], which can be selectively inhibited
by leptomycine B (LMB) [48]. To further characterize
the mechanism of action of STAT3-decoy ODN on
STAT3 nucleo-cytoplasmic shuttling, the cells were
treated with LMB or vanadate. Treatment with LMB (10
ng/ml) increased nuclear STAT3 (Figure 7A, lane 2, and
7C), as previously shown in v-src expressing cells [31]
(it also inhibited STAT3 phosphorylation, in agreement
with previous results [31], see [additional file 3]). Treat-
ment with vanadate (100 μM) or with both LMB and
vanadate also increased nuclear STAT3 (Figure 7A, and
7C). Vanadate (Figure 7B, lane 2) and LMB (Figure 7B,
lane 3) competed with STAT3-decoy ODN and opposed
its action by retaining STAT3 within the nucleus.
Nuclear transfer of activated STAT3 involves karyo-
pherins/importins which interact with the NLS located
within the DBD [3,5]. To verify the possibility of a com-
petition between karyopherin and STAT3-decoy ODN
for STAT3 binding, STAT3 immunoprecipitation and
STAT3-decoy ODN pull-downs were compared to one
another for their karyopherin content. Karyopherin was
detected in the STAT3 immunoprecipitates (Figure 8A,
lane 3) and STAT3 was detected in the karyopherin
immunoprecipitates (lane 4), but neither of them was
detected in the IgG immunoprecipitate control (lane 2).
On the other hand, STAT3-decoy ODN-trapped
STAT3, detected by treating cells with biotinylated
STAT3-decoy ODN (under the conditions shown above
to inhibit STAT3 nuclear transfer; see Figure 2A), col-
lected on avidin-coated agarose beads and analyzed by
western blotting, contained either no karyopherin or
only trace amounts, while clearly containing STAT3
(Figure 8B, lane 2), as previously shown [17]. An identi-
cal experiment performed with mutated STAT3-decoy
ODN showed practically no detectable STAT3 or karyo-
pherin (not shown). The amount of karyopherin
detected in the crude lysates is shown in figures 8A
(lane 1), and 8B (lane 1). The observations reported
here suggest that STAT3-decoy ODN impairs the bind-
ing of STAT3 complexes to karyopherin.
Inhibition of STAT3 with STAT3-decoy ODN in SW 480
cells is associated with inhibition of NF-B
Experiments were conducted to determine whether the
inhibition of STAT3 by STAT3-decoy ODN could indir-
ectly affect NF-B nuclear translocation, since a func-
tional interaction between STAT3 and NF-B has been
reported in several cellular systems [21,34,49]. In the
SW 480 cells, Stattic was found to inhibit the nuclear
transfer of both STAT3 and NF-B (not shown), and to
inhibit NF-B activity as measured with a NF-B-speci-
fic reporter plasmid (not shown). STAT3-decoy ODN,
but not mutated decoy ODN, markedly reduced NF-B
nuclear translocation (Figure 9A, lanes 4 and 8). Pull-
down experiments with STAT3-decoy ODN also
showed higher amounts of NF-B in the complex
obtained from the nuclear fraction of IL-6-treated cells
(Figure 9B, lane 4, and [additional file 4]). TNF-a-stimu-
lated nuclear transfer of NF-B (Figure 9C, lane 4),
which was inhibited by the NF-B-decoy ODN (not
shown), was insensitive to STAT3-decoy ODN (Figure
9C, lane 8); similar results were observed when probing
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the NF-B pull-downs with anti-p65 antibody, except
that the basal levels were somewhat higher (Figure 9C).
The expression of the direct NF-B target I-B, as
determined by qPCR analysis, was inhibited to 50% of
the control level by STAT3-decoy ODN (Figure 9D).
However, TNF-a-induced I-B mRNA remained high in
the presence of STAT3-decoy ODN (Figure 9D). On the
other hand, the expression of cyclin D1, a STAT3 target
gene, was inhibited by STAT3-decoy ODN (Figure 9E).
Thus, a decoy ODN targeting STAT3 can inhibit NF-B
indirectly.
Discussion
Constitutive STAT3 activation is frequently involved in
uncontrolled tumor cell proliferation and therefore con-
stitutes a valuable target for anti-tumor therapy [11,50].
Decoy oligonucleotides (decoy ODNs) have been shown
to efficiently induce cell death in many different cellular
systems (see [51] for review) and to have a potential for
specific targeting of tumor cells. However, although it is
generally assumed that decoy ODNs must enter the
nucleus to exert their inhibitory action on the targeted
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Figure 9 Functional interaction of STAT3 with NF-B in SW 480 cells. A: NF-B nuclear transfer in STAT3-decoy ODN-transfected SW 480
cells. Cells were transfected with STAT3-decoy ODN (ST3dODN) (2 μg/ml) (3 and 4), IL-6 (50 ng/ml, 16 h) (5 and 6), or mutated STAT3-decoy
ODN (mtODN) (7 and 8). Controls: 1 and 2. B: Probe of STAT3-decoy ODN pull-down with NF-B antibody in non-transfected cytoplasm and
nuclear fractions (1 and 2) and in IL-6 (50 ng/ml)-treated cytoplasm and nuclear fractions (3 and 4). C: Analysis of NF-B activity by pull-down
assay with NF-B-decoy ODN following treatment of cells with STAT3-decoy ODN (2 μg/ml). Cells treated with TNF-a (20 ng/ml) (3 and 4)
transfected with STAT3-decoy ODN (2 μg/ml) (lanes 5 and 6), treated with both TNF-a and STAT3-decoy ODN (7 and 8), transfected with
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Western blotting with NF-B antibody (p50 or p65 subunits). D: mRNA levels of the NF-B target I-B (qPCR) after STAT3-decoy ODN treatment.
Cells were not transfected, transfected with STAT3-decoy ODN (ST3dODN) (2 μg/ml), treated with TNF-a (20 ng/ml), treated with both STAT3-
decoy ODN and TNF-a, or transfected with mutated STAT3-decoy ODN (mtdODN) (2 μg/ml) and TNF-a. E: mRNA levels of cyclin-D1 (qPCR) after
treatment with STAT3-decoy ODN. Cells were not treated, treated with TNF-a (20 ng/ml), transfected with STAT3-decoy ODN (2 μg/ml), or
treated with both TNF-a and STAT3-decoy ODN. Results are expressed as % of control.
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TF, little is known of their mechanism of action. To
study this issue, the SW 480 colon carcinoma tumor
cell line was used as a model system. These cells require
a basal level of activated STAT3 for survival [17,41], as
confirmed here by STAT3-specific siRNA- or Stattic-
induced cell death. To analyze the impact of a STAT3-
decoy ODN on the subcellular localization of STAT3 in
the colon carcinoma cell line SW 480, a combination of
subcellular fractionation, oligonucleotide pull-down and
immunofluorescence microscopy was used, in non-sti-
mulated cells in most experiments in order to reproduce
physiological conditions as much as possible. The main
observations of this study are that: i, the STAT3-decoy
ODN interacts with active phospho-STAT3 dimers, ii,
this interaction results in the cytoplasmic trapping of
phospho-STAT3 and iii, blocked nuclear transfer of
active STAT3 by STAT3-decoy ODN results in reduced
cyclin D1 (a key target of STAT3) expression and cell
death induction. STAT3-decoy ODN was found to
interact with activated dimeric STAT3 but not with
non-activated STAT3 (see Figure 1A where STAT3,
although present in the cytoplasmic fraction, does not
interact with the STAT3-decoy ODN and the pull-down
assays of Figure 2 where phospho-STAT3 is brought
down by the STAT3-decoy ODN but not in the pre-
sence of Stattic). The specificity of STAT3 targeting by
STAT3-decoy ODN was further evidenced by the
absence of any effect on STAT3 nuclear transfer of
either a control mutated STAT3-decoy ODN or a decoy
NF-B-ODN. In addition, STAT3-decoy ODN did not
prevent the nuclear transfer of DNA binding domain
(DBD)-mutated STAT3, indicating that a functional
DBD domain is necessary for activated STAT3 to bind
STAT3-decoy ODN. Nuclear entry of proteins involves
a NLS within the protein’s sequence, which allows inter-
action with components of the nuclear membrane pore
complex (NPC). About half of the identified NLS lie
within the DBD of proteins. STAT3 contains several
NLS [32,52], but its major functional NLS lies within
the DBD [3,5]; this dimer-specific NLS appears to be
essential for STAT dimer binding to karyopherin/impor-
tins [53] which mediate interaction with the NPC. This
suggests that STAT3 cytoplasmic trapping by STAT3-
decoy ODN results from the interaction of the decoy
ODN with the DBD domain of a functional STAT3
dimer, thereby masking the NLS and preventing interac-
tion with karyopherin/importins as depicted in Figure
10A. Indeed, STAT3 immunoprecipitation brought
down karyopherin a, while STAT3-decoy ODN pull-
down did not. This observation is in agreement with
studies showing that an ODN containing the m67
sequence can displace the interaction of recombinant
phospho-STAT1 with recombinant importin a [54]. The
observation that STAT3-decoy ODN inhibited only
activated STAT3 suggests that it could effectively inhibit
STAT3 in cells in which there is basal nucleo-cytoplas-
mic shuttling of activated STAT3. Constitutive nucleo-
cytoplasmic shuttling of STAT3 has been observed in
several cell systems [52], including v-src transformed
cells in which STAT3 is activated [31]. Previous
immuno-cytochemistry studies have shown that the
CRM-1 inhibitor LMB interferes with the nucleo-cyto-
plasmic shuttling of STAT3, resulting in its nuclear
accumulation [8,31] and inhibition of tyrosine phosphor-
ylation [31]. In the present study, LMB increased
nuclear localization of STAT3 and prevented the action
of STAT3-decoy ODN, reinforcing the view that the lat-
ter acts on nucleo-cytoplasmic shuttling. Similar results
were obtained with the tyrosine phosphatase inhibitor
vanadate, which increased the amount of nuclear
STAT3, and also prevented the action of STAT3-decoy
ODN, thereby preventing cytoplasmic retention of
STAT3. The modification of total STAT3 subcellular
distribution induced by STAT3-decoy ODN observed
here suggests that STAT3-decoy ODN functions by tar-
geting the nucleo-cytoplasmic traffic itself, as previously
suggested [33]. The data also indicate that STAT3-
decoy ODN impairs the shuttling of active STAT3
dimers only, without interfering with the previously
reported constitutive activation-independent nucleo-
cytoplasmic shuttling of non-phosphorylated dimers
[32,55,56] (see Figure 10). Non-phosphorylated STAT3
was found to be transcriptionally active [57], but
whether it can bind STAT3 consensus sequences is not
clear [58]. Thus, in all likelihood, the inhibitory action
of STAT3-decoy ODN relies on the constitutive activa-
tion of STAT3 in SW 480 cells leading to its nuclear
localization. The specific inhibition of the nucleo-cyto-
plasmic turn-over of STAT3 distinguishes STAT3-decoy
ODN from chemicals, such as Stattic [16], that have
been designed to prevent STAT3 dimer formation by
interacting with the SH2 domain, subsequently impair-
ing nuclear translocation; and from siRNAs, which tar-
get the entire STAT3 protein pool in any cell,
disrupting functions that may be unrelated to growth
and increasing the chances of side effects.
Cell death and apoptosis depend partly on STAT1-
dependent effector genes [46,59] (see also [60] for a
review). In the present study, the suppression of STAT1
by RNA silencing prevented cell death induction by
STAT3-decoy ODN, indicating a critical role for
STAT1, independent of IFNg activation, in line with
previous observations showing STAT1-dependent IFN-
independent cell death [59]; (see also: [61]). However,
STAT1 is the major effector of IFNg, which is antiproli-
ferative or tumoricidal in several cancer cell types
[62,63]; although STAT3-decoy ODN has been found to
induce tumor cell death in several different cell systems
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Figure 10 Nucleo-cytoplasmic shuttling of STAT3, and putative mechanism of action of STAT3-decoy ODN. A: Nucleo-cytoplasmic
shuttling of activated STAT3. Phosphorylation of STAT3 on tyrosine 705 by the JAK family kinases results in dimerization and interaction with
importins (imp), followed by transfer to the nucleus through the nuclear pore complex (NPC). Phospho-STAT3 binds its DNA targets, this is
followed by dephosphorylation by a nuclear tyrosine phosphatase. Unphosphorylated STAT3 re-enters the cytoplasm: this depends in part on
CRM1, which is inhibited by leptomycin B (LMB). Tyrosine phosphatases which dephosphorylate activated JAKs and phospho-STAT3 are inhibited
by sodium vanadate (VO4). Stattic interaction with STAT3 monomers prevents dimerization and nuclear entry. STAT3-decoy ODN (decoy)
interaction with active phosphorylated STAT3 dimers is suggested to compete with importin, thereby trapping active STAT3 in the cytoplasm. B:
Nucleo-cytoplasmic cycling of activated and non-activated STAT3. Non-activated STAT3 cycles in and out of the nucleus in the absence of
activation (phosphorylation: +P) (1, blue arrows). Activated STAT3 enters the nucleus by a transporter-mediated process (1, red arrow) and returns
to the cytoplasm following dephosphorylation: -P) (1, yellow arrow). In STAT3-decoy ODN-transfected cells, cycling of non-activated STAT3 is
unchanged (2, blue arrows), whereas activated (phosphorylated) STAT3 does not enter the nucleus (2, red arrow). NPC: nuclear pore complex.
The scheme in B is adapted from a figure of ref.[3].
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[17,22-24], it can also inhibit STAT1 [17,64]. Despite
their opposing biological effects [65], STAT1 and
STAT3 form heterodimers whose function is unclear
[66]. Thus, despite its efficiency in inducing cell death,
and although it has been found to have few side effects
when administered to primates [67], suggesting a poten-
tial for clinical applications, STAT3-decoy ODN must
be optimized so that it can distinguish between STAT3
and STAT1. Work is in progress to try and define the
structural constraints that underlie specific recognition
of STAT3-decoy ODN by STAT3.
In cancer, STAT3 and NF-B have been shown to
cooperate in promoting cell growth by interacting at
different levels of their activating pathways [35].
STAT3 can trap constitutively activated NF-B within
the nucleus of tumor cells [68]. In SW 480 cells, both
NF-B and STAT3 are activated, suggesting a constitu-
tive interleukin secretory loop, as described for several
tumor cell systems (see: [49]). The findings of the pre-
sent paper indicate that active STAT3 interacts with
NF-B in the colon-carcinoma cell line SW 480, as
shown by the presence of NF-B in STAT3-decoy
ODN pull-downs and by reduced NF-B transcrip-
tional activity. Unphosphorylated STAT3 also interacts
with NF-B, but apparently binds B sites [57], and
may not be recognized by STAT3-decoy ODN for this
reason. Thus, by trapping active STAT3 within the
cytoplasm, STAT3-decoy ODN can simultaneously
trap the fraction of NF-B that is associated to active
STAT3; this may potentially allow the targeting of a
subset of genes that is essential for uncontrolled tumor
cell growth.
Conclusions
STAT3-decoy ODN is an efficient inducer of cell death
in the colon-carcinoma cell line SW 480. It is shown
here to function by trapping activated STAT3 within
the cytoplasm by binding to the active dimer and pre-
venting binding to karyopherin, which is required for
the transfer of active STAT3 into the nucleus. STAT3-
decoy ODN appears to be capable of specifically target-
ing active STAT3, and not its inactive form. Thus,
STAT3-decoy ODN inhibits STAT3 only in cells where
STAT3 is activated, such as cancer cells, resulting in cell
death without harming healthy cells. Furthermore, the
entrapment of STAT3-bound NF-B adds a new power-
ful anticancer potential to STAT3-decoy ODN. These
results point to the DNA binding domain of STAT3, as
well as the process through which activated STAT3
enters the nucleus, as potential sources of active anti-
cancer compounds.
Additional material
Additional file 1: Subcellular localization of the STAT3-decoy ODN.
Cells were grown in 8-well plates to a density of 2.104 cells/mL. When
the cells reached 50-60% confluence, they were transfected with the
FITC-labeled (green) STAT3-decoy ODN (2 μg) in 150 μL of culture
medium (DMEM without Fetal Calf Serum) combined to the liposomes (2
μg of cationic lipid). After 6 h at 37°C in a humidified 5% CO2 incubator,
the cells were placed in fresh FCS-containing medium. After 48 h the
cells were fixed and stained with DAPI to visualize nuclei and examined
by fluorescence microscopy (A: nuclei, B: merge, C: FITC-labeled decoy).
Additional file 2: In-cell STAT3-decoy ODN pull-down assays. Cells
were transfected with the STAT3-decoy ODN, as described under
oligonucleotide transfection (see methods), and then processed by cell
lysis and recovery on avidin-Sepharose beads. After extensive washing
with binding buffer, complexes were separated on SDS-polyacrylamide
(8%) gel, subjected to immunoblotting using an anti-phospho-STAT3
antibody (Cell Signaling); input was determined by analyzing an aliquot
of the initial lysate with STAT3 antibody (Cell Signaling). Results were
analyzed by chemiluminescence (LumiGLO, Cell Signaling) and
autoradiography (X-Omat R, Kodak). In A, cells were either not treated (1)
or treated with decoy STAT3-ODN (2). In B, cells were either not treated
or treated with IL-6 (50 ng/ml).
Additional file 3: Effect of leptomycin B and of vanadate on the
level of phospho-STAT3. Cells were either not treated (1, 2), treated
with leptomycin B (LMB) (5 ng/ml) (3, 4), (10 ng/ml) (5, 6), (15 ng/ml) (7,
8) or vanadate (200 μM) (9, 10) (500 μM) (11, 12), for 4 h. Cytoplasmic (C)
and nuclear extracts (N) (see methods) were analyzed on acrylamide gels
and the membranes probed with anti-phospho-STAT3 and anti-Oct-1
antibodies.
Additional file 4: Effect of the STAT3-decoy ODN and of IL-6 on the
nuclear localization of the p50 subunit of NF-B. Cells were either
not treated (1, 2), treated with STAT3-decoy ODN (2 μg/ml) (3, 4), IL-6 (50
ng/ml) (5, 6) or both (7, 8) for 6 h. Cytoplasmic (C) and nuclear extracts
(N) (see methods) were analyzed on acrylamide gels and the membranes
probed with anti-p50-NF-B and anti-Oct-1 antibodies.
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